BB
Julian Baker
BAKER BROS. ADVISORS LP · Investor
1Y performance ⓘ
+72%
AUM (13F)
$17.4B
# of Holdings
84
3Y performance ⓘ
+58%
vs S&P 500 ⓘ
−14%
Updated
Mar 31
Julian Baker's BAKER BROS. ADVISORS LP holds 84 U.S.-equity positions worth $17.4B (SEC 13F, Q1 2026). Top positions: Incyte Genomics Inc 16.6%, Beone Medicines Ltd. 15.0%, Insmed, Inc. 7.0%. 13F-replication return is +58% over 3 years (-14 pts vs the S&P 500) — a replicated, non-audited figure.
Holdings
| Stock | % of portfolio | Shares | Value | Latest activity | Avg buy price | Current price | Date |
|---|---|---|---|---|---|---|---|
| INCY Incyte Genomics Inc | 16.6% | 30.7M | $2.9B | — | $72.27 | $103.66 (+43%) | 2026-03-31 |
| ONC Beone Medicines Ltd. | 15.0% | 8.8M | $2.6B | — | $215.53 | $271.80 (+26%) | 2026-03-31 |
| INSM Insmed, Inc. | 7.0% | 7.4M | $1.2B | ▲ 13% (+828K) | $17.05 | $98.61 (+478%) | 2026-03-31 |
| MDGL Madrigal Pharmaceuticals, Inc. Common Stock | 6.4% | 2.1M | $1.1B | — | $242.26 | $512.88 (+112%) | 2026-03-31 |
| ACAD Acadia Pharmaceuticals Inc. | 5.5% | 42.9M | $955M | — | $18.82 | $22.09 (+17%) | 2026-03-31 |
| RVMD Revolution Medicines, Inc. Common Stock | 5.3% | 9.6M | $929M | ▲ 1.1% (+100K) | $21.66 | $165.81 (+666%) | 2026-03-31 |
| CELC Celcuity Inc. Common Stock | 5.2% | 7.9M | $904M | — | $9.14 | $89.93 (+884%) | 2026-03-31 |
| KOD Kodiak Sciences Inc Common Stock | 4.4% | 19.9M | $759M | — | $6.20 | $36.63 (+491%) | 2026-03-31 |
| KYMR Kymera Therapeutics, Inc. Common Stock | 4.1% | 8.7M | $721M | — | $29.63 | $99.45 (+236%) | 2026-03-31 |
| SMMT Summit Therapeutics Inc. Common Stock | 4.0% | 36.4M | $690M | — | $1.75 | $14.28 (+716%) | 2026-03-31 |
| PRAX Praxis Precision Medicines, Inc. Common Stock | 3.2% | 1.8M | $565M | ▲ 56% (+627K) | $61.02 | $303.39 (+397%) | 2026-03-31 |
| RYTM Rhythm Pharmaceuticals, Inc. Common Stock | 2.8% | 5.6M | $487M | — | $17.84 | $101.39 (+468%) | 2026-03-31 |
| ALKS Alkermes Inc. plc | 2.0% | 10.0M | $354M | — | $24.10 | $46.02 (+91%) | 2026-03-31 |
| GRAL GRAIL, Inc. Common Stock | 1.2% | 4.0M | $208M | ▲ 93% (+1.9M) | $17.85 | $62.10 (+248%) | 2026-03-31 |
| EWTX Edgewise Therapeutics, Inc. Common Stock | 1.2% | 6.6M | $207M | — | $6.67 | $36.50 (+447%) | 2026-03-31 |
| IONS Ionis Pharmaceuticals, Inc. Common Stock | 0.9% | 2.0M | $154M | ▲ 14% (+256K) | $40.06 | $75.89 (+89%) | 2026-03-31 |
| KNSA Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares | 0.8% | 2.8M | $136M | — | $18.67 | $57.13 (+206%) | 2026-03-31 |
| IMVT Immunovant, Inc. Common Stock | 0.8% | 5.5M | $136M | — | $38.39 | $38.10 (−1%) | 2026-03-31 |
| ROIV Roivant Sciences Ltd. Common Shares | 0.8% | 4.9M | $135M | ▼ 12% (−687K) | $7.38 | $31.25 (+323%) | 2026-03-31 |
| IDYA IDEAYA Biosciences, Inc. Common Stock | 0.8% | 3.9M | $131M | ▲ 9.1% (+328K) | $13.73 | $34.23 (+149%) | 2026-03-31 |
| ARWR Arrowhead Research Corporation | 0.7% | 2.0M | $125M | ▼ 8.4% (−183K) | $15.80 | $82.00 (+419%) | 2026-03-31 |
| STOK Stoke Therapeutics, Inc. Common Stock | 0.6% | 3.3M | $109M | — | $8.33 | $30.97 (+272%) | 2026-03-31 |
| IMTX Immatics N.V. Ordinary Shares | 0.6% | 10.9M | $107M | ▼ 9.7% (−1.2M) | $6.90 | $9.78 (+42%) | 2026-03-31 |
| ABCL AbCellera Biologics Inc. Common Shares | 0.6% | 30.3M | $106M | ▲ 10.0% (+2.8M) | $7.54 | $5.74 (−24%) | 2026-03-31 |
| ABVX Abivax S.a. | 0.6% | 876K | $98M | — | $84.90 | $101.66 (+20%) | 2026-03-31 |
| CRNX Crinetics Pharmaceuticals, Inc. | 0.5% | 2.4M | $85M | ▲ 43% (+703K) | $44.79 | $35.38 (−21%) | 2026-03-31 |
| REPL Replimune Group, Inc. | 0.5% | 11.0M | $84M | — | $17.66 | $11.18 (−37%) | 2026-03-31 |
| CELC 2.75 08/01/31 Celcuity Inc. | 0.4% | 30.8M | $75M | — | $1.33 | — (+83%) | 2026-03-31 |
| NRIX Nurix Therapeutics, Inc. Common stock | 0.4% | 4.7M | $72M | — | $8.88 | $18.65 (+110%) | 2026-03-31 |
| DNLI Denali Therapeutics Inc. Common Stock | 0.4% | 3.7M | $72M | — | $23.04 | $24.05 (+4%) | 2026-03-31 |
| DNTH Dianthus Therapeutics, Inc. Common Stock | 0.4% | 852K | $72M | ▲ 7.9% (+62K) | $18.63 | $87.37 (+369%) | 2026-03-31 |
| GLUE Monte Rosa Therapeutics, Inc. Common Stock | 0.4% | 4.3M | $71M | — | $7.79 | $18.67 (+140%) | 2026-03-31 |
| GPCR Structure Therapeutics Inc. | 0.4% | 1.4M | $69M | — | $43.89 | $45.51 (+4%) | 2026-03-31 |
| TRDA Entrada Therapeutics, Inc. Common Stock | 0.4% | 5.1M | $64M | — | $14.50 | $7.07 (−51%) | 2026-03-31 |
| BCYC Bicycle Therapeutics Plc | 0.3% | 10.9M | $51M | — | $21.27 | $3.98 (−81%) | 2026-03-31 |
| SYRE Spyre Therapeutics, Inc. Common Stock | 0.3% | 1.0M | $50M | — | $14.97 | $100.32 (+570%) | 2026-03-31 |
| RAPP Rapport Therapeutics, Inc. Common Stock | 0.3% | 1.5M | $48M | — | $11.37 | $38.19 (+236%) | 2026-03-31 |
| ALMS Alumis Inc. Common Stock | 0.2% | 2.0M | $44M | ▲ 29% (+450K) | $13.30 | $24.60 (+85%) | 2026-03-31 |
| MIRM Mirum Pharmaceuticals, Inc. Common Stock | 0.2% | 446K | $41M | NEW (+446K) | $31.60 | $107.77 (+241%) | 2026-03-31 |
| VRDN Viridian Therapeutics, Inc. Common Stock | 0.2% | 2.0M | $39M | — | $13.98 | $17.63 (+26%) | 2026-03-31 |
| ELVN Enliven Therapeutics, Inc. Common Stock | 0.2% | 905K | $35M | ▲ 234% (+634K) | $17.59 | $45.96 (+161%) | 2026-03-31 |
| PRLD Prelude Therapeutics Incorporated | 0.2% | 10.1M | $35M | — | $5.70 | $4.32 (−24%) | 2026-03-31 |
| DBVT DBV Technologies S.A. | 0.2% | 1.5M | $31M | — | $3.09 | $15.70 (+408%) | 2026-03-31 |
| DSGN Design Therapeutics, Inc. Common Stock | 0.2% | 2.6M | $28M | ▲ 16% (+353K) | $5.77 | $13.70 (+137%) | 2026-03-31 |
| CNTA Centessa Pharmaceuticals Plc | 0.1% | 671K | $27M | — | $9.03 | $40.18 (+345%) | 2026-03-31 |
| CTMX CytomX Therapeutics, Inc. | 0.1% | 5.0M | $23M | ▲ 17% (+725K) | $2.27 | $3.04 (+34%) | 2026-03-31 |
| JBIO Jade Biosciences, Inc. Common Stock | 0.1% | 1.6M | $23M | — | $15.43 | $19.45 (+26%) | 2026-03-31 |
| IRON Disc Medicine, Inc. Common Stock | 0.1% | 350K | $22M | ▲ 3.7% (+13K) | $63.40 | $70.80 (+12%) | 2026-03-31 |
| IMCR Immunocore Holdings Plc | 0.1% | 734K | $22M | ▼ 68% (−1.6M) | $49.44 | $29.35 (−41%) | 2026-03-31 |
| XENE Xenon Pharmaceuticals Inc | 0.1% | 370K | $22M | — | $35.79 | $54.79 (+53%) | 2026-03-31 |
Showing top 50 of 84 holdings by value.
FAQ ▾
What are Julian Baker's largest holdings?
As of the latest 13F: Incyte Genomics Inc 16.6%, Beone Medicines Ltd. 15.0%, Insmed, Inc. 7.0%, Madrigal Pharmaceuticals, Inc. Common Stock 6.4%, Acadia Pharmaceuticals Inc. 5.5%.
How big is BAKER BROS. ADVISORS LP's 13F portfolio?
$17.4B across 84 disclosed U.S.-equity positions.
What is Julian Baker's 3-year performance?
+58% (13F-replication, price return), -14 pts vs the S&P 500. Not an audited fund return.
Where does this data come from?
U.S. SEC Form 13F-HR institutional holdings filings.
Sourced from SEC Form 13F-HR filings · Not investment advice ▾
Data as of 2026-03-31 · Methodology
13F-replication (price return, filing-date based) — not an audited fund return.
Published by WealthFile · Not investment advice.
Latest activity = change vs. the prior 13F. Avg buy price = est. entry over the trailing 3 years (gain = vs. latest price). Returns are 13F-replication, not audited fund returns. Sourced from SEC 13F filings.